Centro De Ingenieria Genetica Y Biotecnologia

Centro De Ingenieria Genetica Y Biotechnologia

Vivian Huerta Galindo

Glay Chinea Santiago

Osmany Guirola Cruz

Alexis Musacchio Lasa

Noralvis Fleitas Salazar

Osvaldo Reyes Acosta

Hilda Elisa Garay Pérez

Alejandro Miguel Martin Dunn

Patricia Gabriela Toledo Mayora

Mónica Sarría Núñez

Luis Javier González López

Hilda Elisa Garay Perez

Ania Cabrales Rico

Aniel Sánchez Puente

Viviana Falcón Cama

Yuliet Mazola Reyes

Roberto Vera Alvarez

Gabriel Ramon Padron Palomares

Vladimir Armando Besada Perez

Alejandro Miguel Martín Dunn

Olvaldo Reyes Acosta

Luis Javier Gonzalez Lopez

Anìa Cabrales Rico

Monica Sarria Nunez

Aniel Sanchez Puente

Sonia González Blanco

Karen Alvarez Pérez

Rocío Garateix Suárez

Gabriel Jesús Márquez Perera

Alexis Yero Díaz

Dianne Pupo Gómez

Mariela Vázquez Castillo

Gabriel Ramón PADRÓN Palomares

Luis Javier GONZÁLEZ LÓPEZ

Hilda Elisa Garay PÉREZ

Alejandro Miguel MARTÍN Dunn

Vladimir Armando Besada PÉREZ

Dianne Pupo Gomez

Rocio Garateix Suarez

Karen Alvarez Perez

Gabriel Jesus Marquez Perera

Alexis Yero Diaz

Mónica SARRÍA NÚÑEZ

Karen Alvarez PÉREZ

Alexis Yero DÍAZ

Dianne Pupo GÓMEZ

Gabriel Jesús MÁRQUEZ Perera

Rocio Garateix SUÁREZ

Mariela VÁZQUEZ Castillo

Sonia Gonzalez Blanco

Viviana FalcÓn Cama

The present invention discloses structurally constrained synthetic peptides that have been optimized for the formation of a beta hairpin structure. Said peptides are able to inhibit or attenuate Dengue virus (DENV) infections. The invention also discloses pharmaceutical compositions containing these synthetic peptides, which are useful for the prevention and/or treatment of DENV-caused infections. Likewise, the invention disclosed a method for treating infections caused by this virus.

Beta hairpin peptides having antiviral properties against Dengue virus

Use of chemical compounds obtained in silico for the preparation of pharmaceutical compositions to attenuate or inhibit Dengue virus infection. Particularly, through the interference or the modulation of several stages of viral replication cycle related with the entry of virus into host cells and the assembly of mature progeny virions. The invention also comprises the use of such pharmaceutical compositions for prophylactic and/or therapeutic treatment of infection caused by all four serotypes of Dengue virus and other flaviviruses.

[object Object]

The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This invention is also relative to pharmaceutical compounds which contain these chimerical peptides for the prevention and/or treatment of the infection caused by a virus of the Flaviviridae family.

Chimerical peptidic molecules with antiviral properties against the viruses of the Flaviviridae family

The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin.

Method to block the infection by flaviviruses, molecules and uses

Growing community of inventors

Ciudad de la Habana, Cuba

Vivian Huerta Galindo